286 related articles for article (PubMed ID: 33723247)
1. Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC).
Makhov P; Bychkov I; Faezov B; Deneka A; Kudinov A; Nicolas E; Brebion R; Avril E; Cai KQ; Kharin LV; Voloshin M; Frantsiyants E; Karnaukhov N; Kit OI; Topchu I; Fazliyeva R; Nikonova AS; Serebriiskii IG; Borghaei H; Edelman M; Dulaimi E; Golemis EA; Boumber Y
Oncogenesis; 2021 Mar; 10(3):29. PubMed ID: 33723247
[TBL] [Abstract][Full Text] [Related]
2. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.
Kudinov AE; Deneka A; Nikonova AS; Beck TN; Ahn YH; Liu X; Martinez CF; Schultz FA; Reynolds S; Yang DH; Cai KQ; Yaghmour KM; Baker KA; Egleston BL; Nicolas E; Chikwem A; Andrianov G; Singh S; Borghaei H; Serebriiskii IG; Gibbons DL; Kurie JM; Golemis EA; Boumber Y
Proc Natl Acad Sci U S A; 2016 Jun; 113(25):6955-60. PubMed ID: 27274057
[TBL] [Abstract][Full Text] [Related]
3. Musashi-2 (MSI2) regulation of DNA damage response in lung cancer.
Bychkov I; Deneka A; Topchu I; Pangeni RP; Lengner C; Karanicolas J; Golemis EA; Makhov P; Boumber Y
bioRxiv; 2023 Jun; ():. PubMed ID: 37398283
[TBL] [Abstract][Full Text] [Related]
4. Musashi-2 (MSI2) regulation of DNA damage response in lung cancer.
Bychkov I; Deneka A; Topchu I; Pangeni R; Ismail A; Lengner C; Karanicolas J; Golemis E; Makhov P; Boumber Y
Res Sq; 2024 Apr; ():. PubMed ID: 38659828
[TBL] [Abstract][Full Text] [Related]
5. Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancer.
Bychkov I; Topchu I; Makhov P; Kudinov A; Patel JD; Boumber Y
bioRxiv; 2023 Mar; ():. PubMed ID: 37034813
[TBL] [Abstract][Full Text] [Related]
6. Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer.
Bychkov I; Topchu I; Makhov P; Kudinov A; Patel JD; Boumber Y
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173995
[TBL] [Abstract][Full Text] [Related]
7. Musashi-2 in cancer-associated fibroblasts promotes non-small cell lung cancer metastasis through paracrine IL-6-driven epithelial-mesenchymal transition.
Samart P; Heenatigala Palliyage G; Issaragrisil S; Luanpitpong S; Rojanasakul Y
Cell Biosci; 2023 Nov; 13(1):205. PubMed ID: 37941042
[TBL] [Abstract][Full Text] [Related]
8. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC).
Topchu I; Karnaukhov N; Mazitova A; Yugai V; Voloshin M; Tikhomirova M; Kit O; Frantsiyants E; Kharin L; Airapetova T; Ratner E; Sabirov A; Abramova Z; Serebriiskii I; Boumber Y; Deneka A
J Thorac Dis; 2021 Mar; 13(3):1370-1379. PubMed ID: 33841930
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome-wide analysis uncovers the targets of the RNA-binding protein MSI2 and effects of MSI2's RNA-binding activity on IL-6 signaling.
Duggimpudi S; Kloetgen A; Maney SK; Münch PC; Hezaveh K; Shaykhalishahi H; Hoyer W; McHardy AC; Lang PA; Borkhardt A; Hoell JI
J Biol Chem; 2018 Oct; 293(40):15359-15369. PubMed ID: 30126842
[TBL] [Abstract][Full Text] [Related]
10. Musashi-2 Deficiency Triggers Colorectal Cancer Ferroptosis by Downregulating the MAPK Signaling Cascade to Inhibit HSPB1 Phosphorylation.
Meng X; Peng X; Ouyang W; Li H; Na R; Zhou W; You X; Li Y; Pu X; Zhang K; Xia J; Wang J; Zhuang G; Tang H; Peng Z
Biol Proced Online; 2023 Dec; 25(1):32. PubMed ID: 38041016
[TBL] [Abstract][Full Text] [Related]
11. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
12. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
13. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
16. Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
Lypova N; Telang S; Chesney J; Imbert-Fernandez Y
J Biol Chem; 2019 Jul; 294(27):10530-10543. PubMed ID: 31126985
[TBL] [Abstract][Full Text] [Related]
17. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
18. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
Zhao J; Guerrero A; Kelnar K; Peltier HJ; Bader AG
Lung Cancer; 2017 Jun; 108():96-102. PubMed ID: 28625657
[TBL] [Abstract][Full Text] [Related]
19. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
